Is An MGC A Good Investment?
Investment Recommendation MGC is an excellent alternative to S&P 500 Index ETFs like SPY, IVV, and VOO due to its more focused portfolio and slightly higher growth profile. MGC has performed well since its inception in December 2007 and has a competitive expense ratio of 0.07%.
At 2023-01-21, the MGC Pharmaceuticals Ltd. quote is equal to 0.010 AUD. According to our projections, there will be a long-term increase; the “MXC” stock price forecast for 2028-01-14 is 0.0133 AUD. Revenue is expected to be around +33.34 percent with a 5-year investment.
Who Owns MGC?
MGC Diagnostics was acquired by Wilton, Connecticut-based private equity firm Altus Capital Partners in December 2017 for $50.3 million. Under Altus Capital Partners, MGC Diagnostics made three acquisitions of smaller businesses to expand its international presence in Germany, France, and Australia.
Is MGC Pharmaceuticals A Buy?
In the past year, 1 Wall Street analysts have given MGC Pharmaceuticals “buy,” “hold,” and “sell” ratings, and there is currently 1 buy rating for the stock. Investors should “buy” MXC shares, according to the consensus among Wall Street analysts.
Who Owns MGC Pharmaceuticals?
YILING PHARMACEUTICAL CO., LTD., SHIJIAZHUANG
- Breaking Down the Recent Vesuvius Share Price Rally on the NSE - March 23, 2023
- Understanding the Factors Driving Vikas Multicorp’s Share Price on BSE - March 23, 2023
- Analyzing the Major Factors Affecting National Express Share Price in 2021 - March 23, 2023